Comparison of clinical efficacy and safety of weekly GLP-1 receptor agonists dulaglutide and semaglutide - Comparison of clinical efficacy and safety of dulaglutide and semaglutide

Kawasai Medical School0 sites120 target enrollmentJune 10, 2021

ConditionsType 2 diabetes

Overview

Phase: 未知
Intervention: Not specified
Conditions: Type 2 diabetes
Sponsor: Kawasai Medical School
Enrollment: 120
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The primary endpoint was the difference of HbA1c level between 2 groups at 24 weeks. The HbA1c level at 24 weeks was significantly lower in S than D. Reduction in BMI and VFA levels were also more significant in S, BMI: 29.2 to 28.8 vs. 29.4 to 28.1

Registry

who.int

Start Date

June 10, 2021

End Date

March 31, 2023

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Kawasai Medical School

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Type 1 diabetes patient Patients using insulin Patients treated with GLP\-1 receptor agonist within 3 months Patients with a history of severe ketosis, diabetic coma, or precoma within the last 6 months Pregnant or potentially pregnant women and lactating patients Diabetic patients with specific mechanisms and diseases (exocrine pancreatic disease, endocrine disease, drug\-induced, hereditary) Cases during steroid administration Patients with malignant tumors Patients with severe infections, before and after surgery, and with serious trauma Patients with severe liver damage Other cases judged to be inappropriate